

Aerocrine

Pressrelease
April 29, 2011

Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in "lagen (1991:980) om handel med finansiella instrument" it's hereby announced that subscription by exercise of options in Aerocrine the number of shares and votes in Aerocrine has increased as specified in the table below.

	Number of shares and votes
Before subscription	102 247 513
Increase	54 721
After subscription	102 302 234

Solna April 29, 2011
Aerocrine AB (publ.)

For further information, please contact:
Michael Colérus, CFO, +46 8 629 07 85

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on April 29, 2011.